Cargando…

SARS‐CoV‐2 neutralizing antibodies decline over one year and patients with severe COVID‐19 pneumonia display a unique cytokine profile

OBJECTIVES: As coronavirus disease 2019 (COVID-19) rages on worldwide, there is an urgent need to characterize immune correlates of protection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and to identify immune determinants of COVID-19 severity. METHODS: This study exa...

Descripción completa

Detalles Bibliográficos
Autores principales: Vacharathit, Vimvara, Srichatrapimuk, Sirawat, Manopwisedjaroen, Suwimon, Kirdlarp, Suppachok, Srisaowakarn, Chanya, Setthaudom, Chavachol, Inrueangsri, Nanthicha, Pisitkun, Prapaporn, Kunakorn, Mongkol, Hongeng, Suradej, Sungkanuparph, Somnuek, Thitithanyanont, Arunee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442529/
https://www.ncbi.nlm.nih.gov/pubmed/34536610
http://dx.doi.org/10.1016/j.ijid.2021.09.021
_version_ 1783753026335408128
author Vacharathit, Vimvara
Srichatrapimuk, Sirawat
Manopwisedjaroen, Suwimon
Kirdlarp, Suppachok
Srisaowakarn, Chanya
Setthaudom, Chavachol
Inrueangsri, Nanthicha
Pisitkun, Prapaporn
Kunakorn, Mongkol
Hongeng, Suradej
Sungkanuparph, Somnuek
Thitithanyanont, Arunee
author_facet Vacharathit, Vimvara
Srichatrapimuk, Sirawat
Manopwisedjaroen, Suwimon
Kirdlarp, Suppachok
Srisaowakarn, Chanya
Setthaudom, Chavachol
Inrueangsri, Nanthicha
Pisitkun, Prapaporn
Kunakorn, Mongkol
Hongeng, Suradej
Sungkanuparph, Somnuek
Thitithanyanont, Arunee
author_sort Vacharathit, Vimvara
collection PubMed
description OBJECTIVES: As coronavirus disease 2019 (COVID-19) rages on worldwide, there is an urgent need to characterize immune correlates of protection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and to identify immune determinants of COVID-19 severity. METHODS: This study examined the longitudinal profiles of neutralizing antibody (NAb) titers in hospitalized COVID-19 patients clinically diagnosed with mild symptoms, pneumonia, or severe pneumonia, up to 12 months after illness onset, using live-virus neutralization. Multiplex, correlation, and network analyses were used to characterize serum-derived inflammatory cytokine profiles in all severity groups. RESULTS: Peak NAb titers correlated with disease severity, and NAb titers declined over the course of 12 months regardless of severity. Multiplex analyses revealed that IP-10, IL-6, IL-7, and VEGF-α were significantly elevated in severe pneumonia cases compared to those with mild symptoms and pneumonia cases. Correlation and network analyses further suggested that cytokine network formation was distinct in different COVID-19 severity groups. CONCLUSIONS: The study findings inform on the long-term kinetics of naturally acquired serological immunity against SARS-CoV-2 and highlight the importance of identifying key cytokine networks for potential therapeutic immunomodulation.
format Online
Article
Text
id pubmed-8442529
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
record_format MEDLINE/PubMed
spelling pubmed-84425292021-09-15 SARS‐CoV‐2 neutralizing antibodies decline over one year and patients with severe COVID‐19 pneumonia display a unique cytokine profile Vacharathit, Vimvara Srichatrapimuk, Sirawat Manopwisedjaroen, Suwimon Kirdlarp, Suppachok Srisaowakarn, Chanya Setthaudom, Chavachol Inrueangsri, Nanthicha Pisitkun, Prapaporn Kunakorn, Mongkol Hongeng, Suradej Sungkanuparph, Somnuek Thitithanyanont, Arunee Int J Infect Dis Article OBJECTIVES: As coronavirus disease 2019 (COVID-19) rages on worldwide, there is an urgent need to characterize immune correlates of protection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and to identify immune determinants of COVID-19 severity. METHODS: This study examined the longitudinal profiles of neutralizing antibody (NAb) titers in hospitalized COVID-19 patients clinically diagnosed with mild symptoms, pneumonia, or severe pneumonia, up to 12 months after illness onset, using live-virus neutralization. Multiplex, correlation, and network analyses were used to characterize serum-derived inflammatory cytokine profiles in all severity groups. RESULTS: Peak NAb titers correlated with disease severity, and NAb titers declined over the course of 12 months regardless of severity. Multiplex analyses revealed that IP-10, IL-6, IL-7, and VEGF-α were significantly elevated in severe pneumonia cases compared to those with mild symptoms and pneumonia cases. Correlation and network analyses further suggested that cytokine network formation was distinct in different COVID-19 severity groups. CONCLUSIONS: The study findings inform on the long-term kinetics of naturally acquired serological immunity against SARS-CoV-2 and highlight the importance of identifying key cytokine networks for potential therapeutic immunomodulation. The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021-11 2021-09-15 /pmc/articles/PMC8442529/ /pubmed/34536610 http://dx.doi.org/10.1016/j.ijid.2021.09.021 Text en © 2021 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Vacharathit, Vimvara
Srichatrapimuk, Sirawat
Manopwisedjaroen, Suwimon
Kirdlarp, Suppachok
Srisaowakarn, Chanya
Setthaudom, Chavachol
Inrueangsri, Nanthicha
Pisitkun, Prapaporn
Kunakorn, Mongkol
Hongeng, Suradej
Sungkanuparph, Somnuek
Thitithanyanont, Arunee
SARS‐CoV‐2 neutralizing antibodies decline over one year and patients with severe COVID‐19 pneumonia display a unique cytokine profile
title SARS‐CoV‐2 neutralizing antibodies decline over one year and patients with severe COVID‐19 pneumonia display a unique cytokine profile
title_full SARS‐CoV‐2 neutralizing antibodies decline over one year and patients with severe COVID‐19 pneumonia display a unique cytokine profile
title_fullStr SARS‐CoV‐2 neutralizing antibodies decline over one year and patients with severe COVID‐19 pneumonia display a unique cytokine profile
title_full_unstemmed SARS‐CoV‐2 neutralizing antibodies decline over one year and patients with severe COVID‐19 pneumonia display a unique cytokine profile
title_short SARS‐CoV‐2 neutralizing antibodies decline over one year and patients with severe COVID‐19 pneumonia display a unique cytokine profile
title_sort sars‐cov‐2 neutralizing antibodies decline over one year and patients with severe covid‐19 pneumonia display a unique cytokine profile
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442529/
https://www.ncbi.nlm.nih.gov/pubmed/34536610
http://dx.doi.org/10.1016/j.ijid.2021.09.021
work_keys_str_mv AT vacharathitvimvara sarscov2neutralizingantibodiesdeclineoveroneyearandpatientswithseverecovid19pneumoniadisplayauniquecytokineprofile
AT srichatrapimuksirawat sarscov2neutralizingantibodiesdeclineoveroneyearandpatientswithseverecovid19pneumoniadisplayauniquecytokineprofile
AT manopwisedjaroensuwimon sarscov2neutralizingantibodiesdeclineoveroneyearandpatientswithseverecovid19pneumoniadisplayauniquecytokineprofile
AT kirdlarpsuppachok sarscov2neutralizingantibodiesdeclineoveroneyearandpatientswithseverecovid19pneumoniadisplayauniquecytokineprofile
AT srisaowakarnchanya sarscov2neutralizingantibodiesdeclineoveroneyearandpatientswithseverecovid19pneumoniadisplayauniquecytokineprofile
AT setthaudomchavachol sarscov2neutralizingantibodiesdeclineoveroneyearandpatientswithseverecovid19pneumoniadisplayauniquecytokineprofile
AT inrueangsrinanthicha sarscov2neutralizingantibodiesdeclineoveroneyearandpatientswithseverecovid19pneumoniadisplayauniquecytokineprofile
AT pisitkunprapaporn sarscov2neutralizingantibodiesdeclineoveroneyearandpatientswithseverecovid19pneumoniadisplayauniquecytokineprofile
AT kunakornmongkol sarscov2neutralizingantibodiesdeclineoveroneyearandpatientswithseverecovid19pneumoniadisplayauniquecytokineprofile
AT hongengsuradej sarscov2neutralizingantibodiesdeclineoveroneyearandpatientswithseverecovid19pneumoniadisplayauniquecytokineprofile
AT sungkanuparphsomnuek sarscov2neutralizingantibodiesdeclineoveroneyearandpatientswithseverecovid19pneumoniadisplayauniquecytokineprofile
AT thitithanyanontarunee sarscov2neutralizingantibodiesdeclineoveroneyearandpatientswithseverecovid19pneumoniadisplayauniquecytokineprofile